Literature DB >> 15095264

Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck.

David J Arnold1, W Jerry Goodwin, Donald T Weed, Francisco J Civantos.   

Abstract

Despite advances in our ability to safely treat patients with recurrent cancer of the upper aerodigestive tract, outcomes for retreatment are generally poor and the first chance to cure these patients remains the best chance. Thorough knowledge of the outlook and options for patients with recurrent disease is also of significance in choosing therapy for patients with newly diagnosed disease. This is especially true for newly diagnosed patients making the choice between surgery and nonsurgical ("organ-sparing") options, who need to know the outlook for salvage surgery, should they recur after radiation with or without concomitant chemotherapy. Salvage surgery is generally the best option for previously irradiated patients who are faced with resectable, recurrent disease. Unfortunately, the results of surgical salvage are generally poor for patients with advanced stage recurrence and for those who recur after treatment of advanced disease. The site of initial and recurrent disease is important. Surgical salvage is most effective for patients with recurrent laryngeal cancer, least effective for recurrent cancer of the pharynx, and is intermediate for recurrence in the oral cavity. Patients choosing nonsurgical treatment for newly diagnosed cancer of the pharynx cannot rely on salvage surgery in the event of recurrence. Reirraditation for patients who have failed initial treatment that included radiation therapy has been used at a number of institutions with some success. Experience using reirradiation with or without concomitant chemotherapy continues to evolve. Palliative chemotherapy is an option for most patients, but response rates are generally poor and of short duration, after failure of initial treatment that includes radiation therapy. The best approach for many patients and families who face advanced recurrent disease is honest but compassionate communication and supportive care with the help of a hospice organization.

Entities:  

Mesh:

Year:  2004        PMID: 15095264     DOI: 10.1053/j.semradonc.2004.03.001

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  7 in total

1.  Advanced and rapidly progressing head and neck cancer: good palliation following intralesional bleomycin.

Authors:  Keith Ian Quintyne; Shirley Baker; Fintan Wallis; Neville Shine; Rajnish Gupta
Journal:  BMJ Case Rep       Date:  2011-09-19

2.  Treatment and predictive factors in patients with recurrent laryngeal carcinoma: A retrospective study.

Authors:  Peijing Li; Weihan Hu; Yuan Zhu; Jianjiang Liu
Journal:  Oncol Lett       Date:  2015-08-25       Impact factor: 2.967

3.  Salvage surgery for head and neck squamous cell carcinoma.

Authors:  Magis Mandapathil; Marion Roessler; Jochen A Werner; Carl E Silver; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-23       Impact factor: 2.503

4.  Usefulness of cutting needle biopsy in recurrent and advanced staged head and neck malignancies in a palliative setting.

Authors:  G J Ridder; J Pfeiffer
Journal:  Support Care Cancer       Date:  2007-03-21       Impact factor: 3.603

5.  T2-weighted MR imaging early after chemoradiotherapy to evaluate treatment response in head and neck squamous cell carcinoma.

Authors:  A D King; C K Keung; K-H Yu; F K F Mo; K S Bhatia; D K W Yeung; G M K Tse; A C Vlantis; A T Ahuja
Journal:  AJNR Am J Neuroradiol       Date:  2013-01-10       Impact factor: 3.825

6.  Reirradiation of recurrent head and neck cancer using high-dose-rate brachytherapy.

Authors:  V Rudzianskas; A Inciura; E Juozaityte; M Rudzianskiene; R Kubilius; S Vaitkus; M Kaseta; D Adliene
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-10       Impact factor: 2.124

7.  Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance.

Authors:  Salvatore Grisanti; Camillo Almici; Francesca Consoli; Michela Buglione; Rosanna Verardi; Andrea Bolzoni-Villaret; Andrea Bianchetti; Chiara Ciccarese; Monica Mangoni; Laura Ferrari; Gianpaolo Biti; Mirella Marini; Vittorio D Ferrari; Piero Nicolai; Stefano M Magrini; Alfredo Berruti
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.